140 related articles for article (PubMed ID: 23704236)
1. New developments in the management of prostate cancer.
Kantoff PW; Mohler JL
J Natl Compr Canc Netw; 2013 May; 11(5 Suppl):653-7. PubMed ID: 23704236
[TBL] [Abstract][Full Text] [Related]
2. [Castration resistant prostate cancer 2015].
Merseburger AS; Böker A; Kuczyk MA; von Klot CA
Aktuelle Urol; 2015 Jan; 46(1):59-65. PubMed ID: 25658232
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer, version 1.2014.
Mohler JL; Kantoff PW; Armstrong AJ; Bahnson RR; Cohen M; D'Amico AV; Eastham JA; Enke CA; Farrington TA; Higano CS; Horwitz EM; Kawachi MH; Kuettel M; Lee RJ; Macvicar GR; Malcolm AW; Miller D; Plimack ER; Pow-Sang JM; Richey S; Roach M; Rohren E; Rosenfeld S; Small EJ; Srinivas S; Stein C; Strope SA; Tward J; Walsh PC; Shead DA; Ho M;
J Natl Compr Canc Netw; 2013 Dec; 11(12):1471-9. PubMed ID: 24335682
[TBL] [Abstract][Full Text] [Related]
4. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
5. New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
van Dodewaard-de Jong JM; Verheul HMW; Bloemendal HJ; de Klerk JMH; Carducci MA; van den Eertwegh AJM
Clin Genitourin Cancer; 2015 Aug; 13(4):271-279. PubMed ID: 25704270
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
7. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
Cassinello J; Arranz JÁ; Piulats JM; Sánchez A; Pérez-Valderrama B; Mellado B; Climent MÁ; Olmos D; Carles J; Lázaro M
Clin Transl Oncol; 2018 Jan; 20(1):57-68. PubMed ID: 29134562
[TBL] [Abstract][Full Text] [Related]
8. Current treatment strategies for advanced prostate cancer.
Komura K; Sweeney CJ; Inamoto T; Ibuki N; Azuma H; Kantoff PW
Int J Urol; 2018 Mar; 25(3):220-231. PubMed ID: 29266472
[TBL] [Abstract][Full Text] [Related]
9. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
10. Treatment landscape of metastatic prostate cancer: the role of radium-223.
Dermine A; Machiels JP
Acta Clin Belg; 2017 Feb; 72(1):19-23. PubMed ID: 27377415
[TBL] [Abstract][Full Text] [Related]
11. Radium-223 for the treatment of prostate cancer.
Hafeez S; Parker C
Expert Opin Investig Drugs; 2013 Mar; 22(3):379-87. PubMed ID: 23316941
[TBL] [Abstract][Full Text] [Related]
12. Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy.
Garla VV; Salim S; Kovvuru KR; Subauste A
BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 29982185
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review.
Seal BS; Asche CV; Puto K; Allen PD
Value Health; 2013; 16(5):872-90. PubMed ID: 23947983
[TBL] [Abstract][Full Text] [Related]
14. Radium-223 chloride: a new treatment option for metastatic castration-resistant prostate carcinoma.
Pinto A; Cruz P
Drugs R D; 2012 Dec; 12(4):227-33. PubMed ID: 23190319
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
Zustovich F; Fabiani F
Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
[TBL] [Abstract][Full Text] [Related]
16. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
17. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
18. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
Dorff TB; Gross ME
Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
[TBL] [Abstract][Full Text] [Related]
19. New treatment developments applied to elderly patients with advanced prostate cancer.
Mukherji D; Pezaro CJ; Shamseddine A; De Bono JS
Cancer Treat Rev; 2013 Oct; 39(6):578-83. PubMed ID: 23290885
[TBL] [Abstract][Full Text] [Related]
20. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]